Patent litigation for adalimumab resolved in the US European Pharmaceutical Review
AbbVie has announced that it has resolved its US HUMIRA® litigation with Boehringer Ingelheim (BI) and the US license for BI will begin on 1 July 2023.
Patent litigation for adalimumab resolved in the US European Pharmaceutical Review
AbbVie has announced that it has resolved its US HUMIRA® litigation with Boehringer Ingelheim (BI) and the US license for BI will begin on 1 July 2023.